Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,224.80
(
0.64%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.87
(
0.66%
)
Bitcoin
77,568.40
(
-0.91%
)
News Focus
News Focus
Post# of 517558
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Investor2014

Send PM Follow Ignore
Followers 65
Posts 27752
Boards Moderated 0
Alias Born 11/23/2016

Investor2014

Re: OFP post# 170017

Saturday, 10/27/2018 1:24:32 PM

Saturday, October 27, 2018 1:24:32 PM

Post# of 517558
Well DZP was, as per the CTAD 18 presentation, part of KEM analysis without being flagged as significant.

We just don't know if it was because only 1 patient was still on DZP at 148 weeks perhaps in the low concentration cohort or that DZP presents little competition to A2-73 because of its allosteric modulation of not just S1R.

But, yes I guess you could ask Anavex if you really want to know.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News